3 employees of Noida pharma arrested in Uzbek cough syrup death case

Three employees of a Noida-based pharmaceutical firm, whose cough syrup is alleged to have led to the death of 18 children in Uzbekistan last year, were arrested on charges of manufacturing and......

Uzbek cough syrup deaths: Govt to scrap Marion Biotech's licence

The process has been initiated for cancellation of the drug license of pharmaceutical firm Marion Biotech, which is allegedly linked with the death of 18 children in Uzbekistan who consumed their......

DCGI approves market authorisation for Covovax as Covid booster dose

The Drug Controller General of India has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or......

Covaxin gets nod for phase 2, 3 clinical trials on 2-18 year-olds

Bharat Biotech's COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between two to 18 years, official sources said. IMAGE: Kindly......

USTR flags hurdles in medical device exports to India

The USTR report, released just ahead of the US' April 2 deadline for implementing reciprocal tariffs, has also cited high tariffs and price caps, which have not increased in line with inflation, as......

How govt plans to ensure faster availability of new drugs

Given the stringent nature of India’s regulatory environment for clinical trials, several pharmaceutical companies have moved their trials out of India. As a result, only 1.2 per cent of......

6 major companies found manufacturing 'substandard' drugs

  Six pharma majors were sent seven alerts last financial year At least six major pharmaceutical companies, including Cipla, Ipca Labs, Alkem Labs, Morepen Labs, Abbott and Sanofi were found......

Drug regulator 'goes slow' on clinical trials

Files related to clinical trial applications have stopped moving at the drug regulator’s office, according to sources. This is in the wake of stringent directives from the Supreme Court......